跳转至内容
Merck
所有图片(1)

Key Documents

更多文件

15236

Sigma-Aldrich

N,O-双(三甲基硅基)氨基甲酸酯

≥98.0% (T)

别名:

BSC, 三甲基硅烷基 N-三甲基硅烷基氨基甲酸酯

登录查看公司和协议定价
所有图片(1)

About This Item

线性分子式:
(CH3)3SiNHCO2Si(CH3)3
CAS号:
35342-88-2
分子量:
205.40
Beilstein:
2043399
EC號碼:
252-520-4
MDL號碼:
MFCD00040476
分類程式碼代碼:
12352100
PubChem物質ID:
329750791
NACRES:
NA.22

品質等級

100

化驗

≥98.0% (T)

形狀

solid

mp

77-83 °C

SMILES 字串

C[Si](C)(C)NC(=O)O[Si](C)(C)C

InChI

1S/C7H19NO2Si2/c1-11(2,3)8-7(9)10-12(4,5)6/h1-6H3,(H,8,9)

InChI 密鑰

DGIJAZGPLFOQJE-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

相关类别

其他說明

非常适于使醇、酚和羧酸甲硅烷基化的试剂。副产物仅为 CO2 和 NH3；可用于胺的甲硅氧基羰基化反应；以及由羧酰氯合成酰基异氰酸酯

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

個人防護裝備

dust mask type N95 (US), Eyeshields, Gloves

从最新的版本中选择一种：

分析证书(COA)

Lot/Batch Number
048627/1
048627/1V
048627/1V
48627/1
048627/1

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

L. Birkofer et al.
Journal of Organometallic Chemistry, 99, C1 (1975)
Sudarshan Chari et al.
PLoS genetics, 9(8), e1003661-e1003661 (2013-08-13)
The phenotypic outcome of a mutation cannot be simply mapped onto the underlying DNA variant. Instead, the phenotype is a function of the allele, the genetic background in which it occurs and the environment where the mutational effects are expressed.
Yoshitaka Narita et al.
Neuro-oncology, 21(3), 348-359 (2018-12-01)
We conducted a phase III trial of personalized peptide vaccination (PPV) for human leukocyte antigen (HLA)-A24+ recurrent glioblastoma to develop a new treatment modality. We randomly assigned 88 recurrent glioblastoma patients to receive PPV (n = 58) or the placebo
M J Sorich et al.
Annals of oncology : official journal of the European Society for Medical Oncology, 26(1), 13-21 (2014-08-15)
Monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR) prolong survival in metastatic colorectal cancer (mCRC) Kirsten rat sarcoma viral oncogene (KRAS) exon 2 wild-type tumors. Recent evidence has suggested that other RAS mutations (in exons 3 and 4
Ronak Saluja et al.
Journal of oncology practice, 14(5), e280-e294 (2018-03-31)
The purpose of this study was to determine if clinical benefits of novel anticancer drugs, measured by the ASCO Value Framework and European Society of Medical Oncology (ESMO) Magnitude of Clinical Benefit Scale, have increased over time in parallel with
查看所有相关文献

商品

Silylation of Non-Steroidal Anti-Inflammatory Drugs

Results of a study involving the ability few Fluka silylating reagents to form GC-MS-compatible trimethylsilylmethyl derivatives of NSAIDs

Silylation of Non-Steroidal Anti-Inflammatory Drugs

Results of a study involving the ability few Fluka silylating reagents to form GC-MS-compatible trimethylsilylmethyl derivatives of NSAIDs

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门